Evidence map›Paper›PMID 34113568›Full record

ArticleFrontiers in oncology2021

Low miR-214-5p Expression Correlates With Aggressive Subtypes of Pediatric ALCL With Non-Common Histology.

Piero Di Battista, Federica Lovisa, Enrico Gaffo, Ilaria Gallingani, Carlotta C Damanti, Anna Garbin, Lavinia Ferrone, Elisa Carraro, Marta Pillon, Luca Lo Nigro and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 1 country.

Piero Di BattistaDivision of Pediatric Hematology, Oncology and Stem Cell Transplant, Maternal and Child Health Department, University of Padova, Padova, Italy.
Federica LovisaDivision of Pediatric Hematology, Oncology and Stem Cell Transplant, Maternal and Child Health Department, University of Padova, Padova, Italy.
Enrico GaffoDepartment of Molecular Medicine, University of Padova, Padova, Italy.
Ilaria GallinganiDivision of Pediatric Hematology, Oncology and Stem Cell Transplant, Maternal and Child Health Department, University of Padova, Padova, Italy.
Carlotta C DamantiDivision of Pediatric Hematology, Oncology and Stem Cell Transplant, Maternal and Child Health Department, University of Padova, Padova, Italy.
Anna GarbinDivision of Pediatric Hematology, Oncology and Stem Cell Transplant, Maternal and Child Health Department, University of Padova, Padova, Italy.
Lavinia FerroneDivision of Pediatric Hematology, Oncology and Stem Cell Transplant, Maternal and Child Health Department, University of Padova, Padova, Italy.
Elisa CarraroDivision of Pediatric Hematology, Oncology and Stem Cell Transplant, Maternal and Child Health Department, University of Padova, Padova, Italy.
Marta PillonDivision of Pediatric Hematology, Oncology and Stem Cell Transplant, Maternal and Child Health Department, University of Padova, Padova, Italy.
Luca Lo NigroCenter of Pediatric Hematology Oncology, Azienda Policlinico G. Rodolico - San Marco, Catania, Italy.
Rossella MuraDepartment of Paediatric Haematology-Oncology, Ospedale Pediatrico Microcitemico, Cagliari, Italy.
Marco PizziSurgical Pathology and Cytopathology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy.
Vincenza GuzzardoSurgical Pathology and Cytopathology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy.
Angelo Paolo Dei TosSurgical Pathology and Cytopathology Unit, Department of Medicine - DIMED, University of Padova, Padova, Italy.
Alessandra BiffiDivision of Pediatric Hematology, Oncology and Stem Cell Transplant, Maternal and Child Health Department, University of Padova, Padova, Italy.
Stefania BortoluzziDepartment of Molecular Medicine, University of Padova, Padova, Italy.
Lara MussolinDivision of Pediatric Hematology, Oncology and Stem Cell Transplant, Maternal and Child Health Department, University of Padova, Padova, Italy.
University of Padua · ITCittà della Speranza Foundation · ITOspedale Microcitemico · ITPoliclinico Universitario di Catania · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The unsatisfactory cure rate of relapsing ALK-positive Anaplastic Large-Cell Lymphoma (ALCL) of childhood calls for the identification of new prognostic markers. Here, the small RNA landscape of pediatric ALK-positive ALCL was defined by RNA sequencing. Overall, 121 miRNAs were significantly dysregulated in ALCL compared to non-neoplastic lymph nodes. The most up-regulated miRNA was miR-21-5p, whereas miR-19a-3p and miR-214-5p were reduced in ALCL. Characterization of miRNA expression in cases that relapsed after first line therapy disclosed a significant association between miR-214-5p down-regulation and aggressive non-common histology. Our results suggest that miR-214-5p level may help to refine the prognostic stratification of pediatric ALK-positive ALCL.

Indexed as

ALCLbiomarkerchildhoodmiRNAprognosisRNA-seq

Identifiers

PMID34113568
PMCPMC8185221
OpenAlexW3164162998

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.